×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth
"Latigo Biotherapeutics has been granted FDA Fast Track Designation for LTG-001, a potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain
03 Mar 2025
Latigo Biotherapeutics ("Latigo") announced the U.S. Food and Drug Administration (FDA) has
...
Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate
Pyros Pharma announces VIGPODER™ (vigabatrin)
Dipal Doshi has been elected to Azenta's Board of Directors
Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status
Avantor® Expands Stability and Microbial Testing Facility to Enhance U.S. Biomanufacturing Infrastructure
By
Avantor and Financial News
Avantor and Financial News
14 Apr 2026
Recent Innovations Showcased by Baxter
By
Baxter International Inc.
Baxter International Inc.
13 Apr 2026
Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro
By
Ro
Ro
09 Apr 2026
Approval and Launch of Nintedanib Capsules
By
Dexcel Pharma USA
Dexcel Pharma USA
09 Apr 2026
When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots
By
BD
BD
07 Apr 2026
Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences
By
Curve Biosciences
Curve Biosciences
07 Apr 2026
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
Medicines Discovery Catapult and Crown Bioscience form a global alliance for radiopharmaceutical innovation
By
Crown Bioscience and Medicines Discovery Catapult
Sep 12
BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.
By
BerGenBio ASA
Jul 29
Aileron Therapeutics will present Phase 1b trial data on low-dose LTI-03 for IPF at the 22nd International Colloquium on Lung and Airway Fibrosis
By
Aileron Therapeutics, Inc.
Oct 11
April
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe for e-Newsletter Monthly
Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
Email
I consent to subscribing to the selected email lists.
Enter the code below
Subscribe
1
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand